To the Editor: Davis and colleagues recently described outcomes for Indigenous and non-Indigenous people in the Northern Territory who received antiviral therapy for chronic hepatitis C virus (HCV) infection.1 They showed similar outcomes when comparing eight Indigenous people with 88 non-Indigenous people who were assessed for sustained virological response (SVR) after interferon-based treatment — SVR was achieved by 50% and 61%, respectively. Outcomes of therapy for HCV infection in Indigenous Australians had not previously been reported.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
No relevant disclosures.